Pertuzumab, Trastuzumab

Pertuzumab and Trastuzumab are two monoclonal antibodies used in combination to treat certain types of breast cancer. They are specifically designed to target and inhibit the growth of cancer cells that overexpress the HER2 protein, a well-known marker for aggressive breast cancer.
Pertuzumab, also known as Perjeta, is a humanized monoclonal antibody that binds to the HER2 receptor, blocking its activation and interfering with the growth and spread of cancer cells. Trastuzumab, or Herceptin, is another monoclonal antibody that binds to the same HER2 receptor, promoting the death of cancer cells and inhibiting their growth and spread.
The combination of Pertuzumab and Trastuzumab has been shown to be more effective than Trastuzumab alone in treating HER2-positive breast cancer. This combination therapy is typically used in the neoadjuvant setting, meaning it is administered before surgery to shrink the tumor and increase the chances of successful breast-conserving surgery. It is also used in the adjuvant setting, following surgery, to reduce the risk of cancer recurrence.
The administration of Pertuzumab and Trastuzumab is typically given as an intravenous infusion over a period of several minutes to an hour. The treatment regimen usually consists of several cycles, with regular monitoring of the patient’s response and potential side effects.
Some common side effects of this combination therapy include flu-like symptoms, nausea, diarrhea, and skin reactions at the injection site. More severe side effects, such as heart problems, can also occur, so it is essential for patients to undergo regular monitoring and reporting of any adverse reactions.